April 3, 2024 04:14 AM EDTUpdated 07:34 AM
Deals

Gen­mab fu­els AD­C­s' hot streak with $1.8B buy­out of Pro­found­Bio

Amber Tong

Dan­ish an­ti­body spe­cial­ist Gen­mab is pay­ing $1.8 bil­lion in cash to scoop up Pro­found­Bio and throw its hat in­to the packed an­ti­body-drug con­ju­gate ring. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times